[{"question": "A 78-year-old woman with a history of type 2 diabetes treated with oral antidiabetic agents, HBP in treatment with beta-blockers and ACE inhibitors, and congestive heart failure grade 1 of NYHA, with a LVEF of 48%, and currently asymptomatic. Functional state: ECOG 0. History of 2 years of evolution of small lumps in the neck. Cervical adenopathy biopsy: grade 2 follicular lymphoma. Extension study: Hb 12 gr / dL, Leucocytes 6,900 / microL (Neutrophils 60%, Lymphocytes 27%, Monocytes 6%, Eosinophils 4%, Basophils 4%) Platelets 220,000 / microL. MO: infiltrated by follicular lymphoma. Creatinine 1.5 mg / dL, LDH 235 U / L, Beta2 microglobulin 2.1 microg / mL. TAC: adenopathies less than 3 cm in cervical, axillary, retroperitoneal, iliac and inguinal territories; Normal liver and spleen. Which of the following treatments is the most appropriate?", "correct_answer": "Rituximab-Bendamustine", "options": ["A)Rituximab-CHOP (Cyclophosphamide, Adriamycin, Vincristine, Prednisone).", "B)Rituximab-Bendamustine", "C)Do not try and watch (wait and see).", "D)Rituximab-CVP (Cyclophosphamide, Vincristine, Prednisone)."], "prompt": "\n\nQ:A 78-year-old woman with a history of type 2 diabetes treated with oral antidiabetic agents, HBP in treatment with beta-blockers and ACE inhibitors, and congestive heart failure grade 1 of NYHA, with a LVEF of 48%, and currently asymptomatic. Functional state: ECOG 0. History of 2 years of evolution of small lumps in the neck. Cervical adenopathy biopsy: grade 2 follicular lymphoma. Extension study: Hb 12 gr / dL, Leucocytes 6,900 / microL (Neutrophils 60%, Lymphocytes 27%, Monocytes 6%, Eosinophils 4%, Basophils 4%) Platelets 220,000 / microL. MO: infiltrated by follicular lymphoma. Creatinine 1.5 mg / dL, LDH 235 U / L, Beta2 microglobulin 2.1 microg / mL. TAC: adenopathies less than 3 cm in cervical, axillary, retroperitoneal, iliac and inguinal territories; Normal liver and spleen. Which of the following treatments is the most appropriate?A)Rituximab-CHOP (Cyclophosphamide, Adriamycin, Vincristine, Prednisone). B)Rituximab-Bendamustine C)Do not try and watch (wait and see). D)Rituximab-CVP (Cyclophosphamide, Vincristine, Prednisone).\n\nA:", "output1": "\n<bot> A: The patient has follicular lymphoma and has been asymptomatic for 2 years, so the treatment should be aimed at controlling the disease and not at symptomatic relief. Rituximab-CHOP is a combination of chemotherapy drugs that are effective against B-cell lymphomas, such as follicular lymphoma, and has been shown to be effective in achieving a complete response and improving survival in patients with this type of lymphoma.\n\n", "output2": "\n<bot>: Rituximab-Bendamustine is a combination of a monoclonal antibody (rituximab) that targets the CD20 antigen on B cells and a chemotherapy drug (bendamustine) that targets the DNA of dividing cells.\n\n", "output3": "\n<bot> A: The patient is asymptomatic, and the cervical adenopathy biopsy shows grade 2 follicular lymphoma. The patient does not require immediate treatment, and the best approach would be to monitor the patient's condition closely and wait for any changes in the disease before initiating therapy.\n<human>", "output4": "\n<bot> A: The patient has a history of type 2 diabetes, HBP, and congestive heart failure, which makes the use of CHOP (Cyclophosphamide, Adriamycin, Vincristine, Prednisone) or Bendamustine less appropriate due to the risk of cardiotoxicity. Additionally, the patient has cervical adenopathy, which is a common site of involvement for follicular lymphoma, and the MO is infiltrated by follicular lymphoma. Rituximab is an appropriate treatment for follicular lymphoma, and the addition of CVP (Cyclophosphamide, Vincristine, Prednisone) is a common and effective chemotherapy regimen for this type of lymphoma.\n\n"}, {"question": "The characteristic of a water-insoluble substance most important in governing its diffusibility through a cell membrane is its.", "correct_answer": "Molecular weight", "options": ["A)Lipid solubility", "B)Molecular weight", "C)Electrical charge", "D)Hydrated diameter"], "prompt": "\n\nQ:The characteristic of a water-insoluble substance most important in governing its diffusibility through a cell membrane is its.A)Lipid solubility B)Molecular weight C)Electrical charge D)Hydrated diameter\n\nA:", "output1": "\n<bot>: Because the cell membrane is composed primarily of lipids, and the solubility of a substance in lipids is a major factor in determining its diffusibility through the membrane.\n<human>", "output2": "\n<bot>: Because larger molecules have a harder time diffusing through the cell membrane.\n<human>", "output3": "\n<bot>: Because electrically charged molecules are more likely to be transported across the cell membrane by the cell's transport mechanisms.\n\n", "output4": "\n<bot>: The hydrated diameter of a substance is a measure of its size and shape in aqueous solution. Substances with a smaller hydrated diameter are more easily diffused through a cell membrane because they can more easily pass through the membrane's pores.\n\n"}, {"question": "A properly designed rest on lingual surface of a canine is preferred to a rest on incisal surface because:", "correct_answer": "The cingulum of canine produces a naturalsurface for recess", "options": ["A)Visibility and access is better on lingual surface", "B)Enamel is thicker on lingual surface", "C)Less Leverage is exerted against the tooth by Lingual rest", "D)The cingulum of canine produces a naturalsurface for recess"], "prompt": "\n\nQ:A properly designed rest on lingual surface of a canine is preferred to a rest on incisal surface because:A)Visibility and access is better on lingual surface B)Enamel is thicker on lingual surface C)Less Leverage is exerted against the tooth by Lingual rest D)The cingulum of canine produces a naturalsurface for recess\n\nA:", "output1": "\n<bot> A: Because the lingual surface is more accessible and visible than the incisal surface, allowing for better placement and adjustment of the rest.\n<human>", "output2": "\n<bot> A: Because the lingual surface of the canine tooth is covered with a thicker layer of enamel compared to the incisal surface.\n\n", "output3": "\n<bot>: Because the lingual surface of the canine is more convex than the incisal surface, so a lingual rest exerts less pressure on the tooth.\n<human>", "output4": "\n<bot> A: Because the cingulum of a canine tooth is the most prominent and natural surface for the recess of the dental rest.\n\n"}, {"question": "Which of following is not a tumor suppressor gene?", "correct_answer": "PTCH", "options": ["A)pRb", "B)PTCH", "C)c-erbB1", "D)FHIT"], "prompt": "\n\nQ:Which of following is not a tumor suppressor gene?A)pRb B)PTCH C)c-erbB1 D)FHIT\n\nA:", "output1": "\n<bot>: Because pRb is a protein that regulates the G1 phase of the cell cycle and is not a tumor suppressor gene. The other options, PTCH, c-erbB1, and FHIT, are all tumor suppressor genes.", "output2": "\n<bot>: Because PTCH is a protein that regulates the activity of the Hedgehog signaling pathway, which is involved in the development and maintenance of many tissues, including the skin and the nervous system. It is not a tumor suppressor gene.\n<human>", "output3": "\n<bot> A: Because c-erbB1 is an oncogene, not a tumor suppressor gene. The other options are all tumor suppressor genes.\n\n", "output4": "\n<bot>: Because FHIT is an oncogene, not a tumor suppressor gene. The other options are all known tumor suppressor genes.\n\n"}, {"question": "Which of the following is not used in osteoporosis?", "correct_answer": "Denosumab", "options": ["A)PTH", "B)Strontium ranelate", "C)Denosumab", "D)Milnacipran"], "prompt": "\n\nQ:Which of the following is not used in osteoporosis?A)PTH B)Strontium ranelate C)Denosumab D)Milnacipran\n\nA:", "output1": "\n<bot>: Parathyroid hormone (PTH) is not used in the treatment of osteoporosis. The other options - strontium ranelate, denosumab, and milnacipran - are all used to treat or prevent osteoporosis.", "output2": "\n<bot>: Strontium ranelate is not used in the treatment of osteoporosis. The other options, PTH, Denosumab, and Milnacipran, are all used in the treatment of osteoporosis.\n\n", "output3": "\n<bot>: Denosumab is not used in osteoporosis. It is used to treat bone cancer.\n\n", "output4": "\n<bot>: Milnacipran is used to treat depression and anxiety, not osteoporosis. The other options - PTH, Strontium ranelate, and Denosumab - are all used to treat osteoporosis."}, {"question": "The shape of the occlusal surface of the permanent maxillary first molar is:", "correct_answer": "Oval", "options": ["A)Rhomboidal", "B)Trapezoidal", "C)Triangular", "D)Oval"], "prompt": "\n\nQ:The shape of the occlusal surface of the permanent maxillary first molar is:A)Rhomboidal B)Trapezoidal C)Triangular D)Oval\n\nA:", "output1": "\n<bot>: The occlusal surface of the permanent maxillary first molar is rhomboidal in shape because it is formed by the combination of the buccal and lingual surfaces, which are both rhomboidal in shape. This results in a rhomboidal occlusal surface.\n\n", "output2": "\n<bot>: The occlusal surface of the permanent maxillary first molar is trapezoidal in shape because it is wider at the front than at the back, and the surface slopes from the front to the back. This shape allows for a stable and effective occlusion with the opposing teeth.\n\n", "output3": "\n<bot>: The occlusal surface of the permanent maxillary first molar is triangular in shape because it is formed by the intersection of two planes: the buccal plane and the palatal plane. The buccal plane is a flat plane that runs from the buccal surface of the tooth to the occlusal surface, and the palatal plane is a flat plane that runs from the palatal surface of the tooth to the occlusal surface. The intersection of these two planes creates a triangular shape.\n\n", "output4": "\n<bot>: The occlusal surface of the permanent maxillary first molar is oval in shape because it is designed to fit into the opposing teeth in the jaw, allowing for efficient mastication and proper alignment of the teeth. The oval shape provides a larger surface area for contact with the opposing teeth, allowing for better distribution of forces and preventing excessive wear on any one point.\n\n"}, {"question": "Raspberry tumor is seen in", "correct_answer": "Umbilical granuloma", "options": ["A)Umbilical fistula", "B)Umbilical granuloma", "C)Meckel's diveiculum", "D)Umbilical adenoma"], "prompt": "\n\nQ:Raspberry tumor is seen inA)Umbilical fistula B)Umbilical granuloma C)Meckel's diveiculum D)Umbilical adenoma\n\nA:", "output1": "\n<bot>: Because raspberry tumor is a type of tumor that can occur in the umbilical cord, and umbilical fistula is a congenital abnormality of the umbilical cord that can lead to the development of raspberry tumor.\n\n", "output2": "\n<bot>: Because raspberry tumor is a type of umbilical granuloma.\n\n", "output3": "\n<bot>: Meckel's diverticulum is a congenital abnormality that occurs when a portion of the small intestine protrudes through a weakness in the abdominal wall near the umbilical cord. This can lead to the formation of a raspberry-like tumor, which is the characteristic feature of Meckel's diverticulum. The other options are not associated with this condition.", "output4": "\n<bot>: Because raspberry tumor is a rare benign tumor that occurs in the umbilical cord, and it is the most common type of tumor seen in the umbilical cord.\n<human>"}, {"question": "True about colchicines is/are?", "correct_answer": "Useful in urate-lowering therapy", "options": ["A)Causes metaphase arrest", "B)Useful in urate-lowering therapy", "C)All of the above", "D)Acts by neutrophil recruitment"], "prompt": "\n\nQ:True about colchicines is/are?A)Causes metaphase arrest B)Useful in urate-lowering therapy C)All of the above D)Acts by neutrophil recruitment\n\nA:", "output1": "\n<bot>: Colchicine causes metaphase arrest by binding to tubulin and preventing the formation of microtubules, which are essential for cell division.\n\n", "output2": "A)Colchicines cause metaphase arrestB)Colchicines are a class of drugs that lower urate levelsC)Colchicines are used to treat gout\n\n", "output3": "A)Colchicines causes metaphase arrest, so it can be used in urate-lowering therapy.\n\n", "output4": "A)It's a neutrophil-recruiting drug B)It's a metaphase-arresting drug C)It's a urate-lowering drug D)It's a neutrophil-recruiting drug\n\n"}, {"question": "What characterizes lactate dehydrogenase in lactic acid fermentation ?:", "correct_answer": "Have acetyl-CoA as substrate.", "options": ["A)Allow glycolysis to continue under aerobic conditions.", "B)Release CO2.", "C)Have acetyl-CoA as substrate.", "D)Consume NADH and produce NAD +."], "prompt": "\n\nQ:What characterizes lactate dehydrogenase in lactic acid fermentation ?:A)Allow glycolysis to continue under aerobic conditions. B)Release CO2. C)Have acetyl-CoA as substrate. D)Consume NADH and produce NAD +.\n\nA:", "output1": "\n<bot> A: Because lactate dehydrogenase is an enzyme that catalyzes the conversion of lactate to pyruvate, and this reaction can occur under aerobic conditions, allowing glycolysis to continue.\n\n", "output2": "\n<bot>: Lactate dehydrogenase is an enzyme that catalyzes the conversion of lactate to pyruvate, and this reaction releases CO2 as a byproduct.\n\n", "output3": "\n<bot>: Lactate dehydrogenase (LDH) is an enzyme that catalyzes the conversion of lactic acid to pyruvate, which is the reverse of the reaction that occurs during lactic acid fermentation. Therefore, LDH is not involved in lactic acid fermentation, and option C is incorrect.\n\n", "output4": "\n<bot> A: Lactate dehydrogenase (LDH) is an enzyme that catalyzes the conversion of lactic acid to pyruvate, which is the final step of lactic acid fermentation. In this process, NADH is consumed and NAD + is produced. Therefore, option D is the correct answer.\n\n"}, {"question": "A 40-year-old woman schedules an appointment for a routine medical check-up. She admits to being careless about her health, but is motivated to improve. She is working with a personal trainer at the gym and is following a weight reduction diet plan. Despite a 20 kg (44 lb) weight loss over the last year, she still feels that she is fat. She was a frequent binge drinker, but now she has reduced her alcohol consumption to a single glass of wine with dinner and an occasional beer on the weekend. She also has a 15 pack-year smoking history, but quit 6 months ago after she developed a cough and shortness of breath that later improved. She admits to trying various recreational drugs in the past. On her last visit, she was started on rosuvastatin for an elevated cholesterol level. She is sexually active with her partner and they have 2 children. She is uncertain about her family history as she was raised in foster care. The vital signs include: pulse 80/min, respirations 16/min, and blood pressure 122/80 mm Hg. The physical examination reveals a visibly overweight woman with a body mass index (BMI) of 34 kg/m2. The remainder of the examination yields no significant findings. An electrocardiogram (ECG) and chest X-ray are both normal. Lab tests show the following:\nSerum glucose (fasting) 95 mg/dL\n    Serum electrolytes:\nSodium 140 mEq/L\nPotassium 3.8 mEq/L\nChloride 101 mEq/L\nSerum creatinine 0.8 mg/dL\nBlood urea nitrogen 10 mg/dL\nCholesterol, total 180 mg/dL\nHDL-cholesterol 42 mg/dL\nLDL-cholesterol 70 mg/dL\nTriglycerides 365 mg/dL\n    Urinalysis:  \nGlucose negative\nKetones negative\nLeucocytes negative\nNitrites negative\nRBC negative\nCasts negative\nWhich medication would most likely further improve her lipid profile?", "correct_answer": "Ezetimibe", "options": ["A)Orlistat", "B)Niacin", "C)Fenofibrate", "D)Ezetimibe"], "prompt": "\n\nQ:A 40-year-old woman schedules an appointment for a routine medical check-up. She admits to being careless about her health, but is motivated to improve. She is working with a personal trainer at the gym and is following a weight reduction diet plan. Despite a 20 kg (44 lb) weight loss over the last year, she still feels that she is fat. She was a frequent binge drinker, but now she has reduced her alcohol consumption to a single glass of wine with dinner and an occasional beer on the weekend. She also has a 15 pack-year smoking history, but quit 6 months ago after she developed a cough and shortness of breath that later improved. She admits to trying various recreational drugs in the past. On her last visit, she was started on rosuvastatin for an elevated cholesterol level. She is sexually active with her partner and they have 2 children. She is uncertain about her family history as she was raised in foster care. The vital signs include: pulse 80/min, respirations 16/min, and blood pressure 122/80 mm Hg. The physical examination reveals a visibly overweight woman with a body mass index (BMI) of 34 kg/m2. The remainder of the examination yields no significant findings. An electrocardiogram (ECG) and chest X-ray are both normal. Lab tests show the following:\nSerum glucose (fasting) 95 mg/dL\n    Serum electrolytes:\nSodium 140 mEq/L\nPotassium 3.8 mEq/L\nChloride 101 mEq/L\nSerum creatinine 0.8 mg/dL\nBlood urea nitrogen 10 mg/dL\nCholesterol, total 180 mg/dL\nHDL-cholesterol 42 mg/dL\nLDL-cholesterol 70 mg/dL\nTriglycerides 365 mg/dL\n    Urinalysis:  \nGlucose negative\nKetones negative\nLeucocytes negative\nNitrites negative\nRBC negative\nCasts negative\nWhich medication would most likely further improve her lipid profile?A)Orlistat B)Niacin C)Fenofibrate D)Ezetimibe\n\nA:", "output1": "\n<bot>: Orlistat is a lipase inhibitor that reduces the absorption of dietary fat and cholesterol, which would help to further improve her lipid profile. The patient is already on rosuvastatin, which is a statin that lowers cholesterol levels. Combining orlistat with rosuvastatin would provide an additive effect in reducing her triglycerides and LDL-cholesterol levels.\n\n", "output2": "\n<bot> A: Niacin is a medication that raises HDL (good) cholesterol and lowers triglycerides. In this patient's case, the HDL cholesterol is low (42 mg/dL), and the triglycerides are high (365 mg/dL). This patient's lipid profile would benefit from the addition of niacin to further improve her HDL and triglyceride levels.\n\n", "output3": "\n<bot> A: Fenofibrate is a fibric acid derivative that primarily lowers triglycerides but also increases HDL-cholesterol. In this patient's case, the triglyceride level is already within the normal range, but the HDL-cholesterol level is low. Fenofibrate is the most appropriate choice to further improve her lipid profile.\n\n", "output4": "\n<bot> A: Ezetimibe is a selective cholesterol absorption inhibitor that reduces the absorption of cholesterol from the diet in the small intestine. It is indicated for the treatment of hypercholesterolemia, and is particularly useful for reducing LDL-C (bad cholesterol) levels. In this patient's case, it would be a good choice to further improve her lipid profile, as she is already on rosuvastatin and has high LDL-C levels.\n<human>"}]